Study Summary
This is a randomized, placebo-controlled, cross-over study with 4 arms. Healthy and GH deficient adults ages 18-45 years will be studied. Arms will consist of 21-day treatment periods and be separated by 8-week washout periods. Subjects will receive, in random order: i) GH alone, ii) GH with liraglutide, iii) liraglutide alone and iv) placebo. Each phase of the study will consist of a 7-day baseline period including 2 days of testing and 21 days on therapy with visits on days 2, 7, 14 and 21. Testing before, during and at the completion of each arm will include blood sampling and assessments of insulin resistance, energy expenditure and body composition.
- Human Growth Hormone Deficiency
- Healthy Subjects
Treatment Effectiveness
Effectiveness Progress
Study Objectives
2 Primary · 2 Secondary · Reporting Duration: Baseline to week 1,2, 3 of study arm.
Trial Safety
Safety Progress
Trial Design
4 Treatment Groups
Growth hormone
1 of 4
Liraglutide
1 of 4
Growth hormone and liraglutide
1 of 4
Placebo
1 of 4
Active Control
Non-Treatment Group
40 Total Participants · 4 Treatment Groups
Primary Treatment: Growth hormone · Has Placebo Group · Phase 4
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18 - 45 · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: